Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock

February 24, 2016 updated by: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Prognostic Value of Circulating microRNAs in Patients With ST-elevation Myocardial Infarction (STEMI) Complicated by Cardiogenic Shock

The aim of the study is knowing the prognostic value of circulating miRNAs in patients admitted to our hospital with STEMI complicated with cardiogenic shock.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

142

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Spain
- - Barcelona, Spain, 08026
    - Recruiting
    - Hospital de La Santa Creu i Sant Pau
    - Contact:
      
      Jordi Sans Roselló, M.D
      
      Phone Number: +34618779109
      
      Email: jsans@santpau.cat
    - Principal Investigator:
      
      JordI Sans-Roselló, M.D.
    - Sub-Investigator:
      
      Alessandro Sionis, M.D.
    - Sub-Investigator:
      
      Judit Cubedo, PhD
    - Sub-Investigator:
      
      Montserrat Vila, M.D.
    - Sub-Investigator:
      
      Albert Durán-Cambra, M.D.
    - Sub-Investigator:
      
      Rosa Suades, PhD
    - Sub-Investigator:
      
      Laia Carla Belarte-Tornero, M.D.
    - Sub-Investigator:
      
      Lina Badimón, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients admitted to Hospital de la Santa Creu i Sant Pau with diagnosis of STEMI with or without cardiogenic shock

Description

Inclusion Criteria:

Age > 18 years
ST elevation by ECG diagnostic of STEMI
Evidency of coronary occlusion in coronariography
Signed informed consent

Exclusion Criteria:

Patients admitted from other hospitals
Impossibility of getting blood samples in first 6h
Declined consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
Cardiogenic Shock STEMI Patients admitted to the hospital with the diagnosis with STEMI complicated with cardiogenic shock
No Cardiogenic Shock STEMI Patients admitted to the hospital with the diagnosis with STEMI without cardiogenic shock

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Mortality Time Frame: up to 6 months	up to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Collaborators

Spanish Society of Cardiology

Investigators

Principal Investigator: Jordi Sans-Roselló, M.D., Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2016

Primary Completion (Anticipated)

August 1, 2016

Study Completion (Anticipated)

February 1, 2017

Study Registration Dates

First Submitted

February 22, 2016

First Submitted That Met QC Criteria

February 24, 2016

First Posted (Estimate)

February 25, 2016

Study Record Updates

Last Update Posted (Estimate)